Kawasaki disease, also known as Kawasaki syndrome, is an acute febrile illness of unknown cause that primarily affects children younger than 5 years of age.

KD-CAAP proof of viability study assesses the effectiveness of adding steroids to standard treatment in children with Kawasaki Disease.

Why is it important to improve paediatric patient’s lives? How is c4c supporting this study?

Listen to our podcast with Prof. Paul Brogan, joined chief investigator of the KD-CAAP trial!